source
- Scholar Rock removes Indiana manufacturing site from SMA drug application after FDA cites deficienciesScholar Rock, a Massachusetts biotech, announced it is withdrawing an Indiana manufacturing facility from its filing for a prospective spinal muscular atrophy (SMA) therapy. The decision follows a…
- Denali Therapeutics' Avlayah generates $3.6M in Q1, beating forecastsDenali Therapeutics reported that its newly launched Hunter syndrome therapy Avlayah earned $3.6 million in revenue during the first quarter after its April market entry. Analysts had projected ro…